Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Genital Herpes Pipeline Drugs Market Overview

Genital Herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

The Genital Herpes – drugs in development research report provides a comprehensive overview on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Genital herpes and features dormant and discontinued projects.

Key Targets DNA, DNA Helicase, DNA Primase, Envelope Glycoprotein D, Lipopolysaccharide, and Matrix Metalloproteinase 9
Key Mechanisms of action DNA Helicase Inhibitor, DNA Primase Inhibitor, DNA Synthesis Inhibitor, Lipopolysaccharide Inhibitor, and Matrix Metalloproteinase 9 Inhibitor
Key Routes of Administration Topical, Oral, Intramuscular, Vaginal, Nasal, Intradermal, Ophthalmic, and Subcutaneous
Key Molecule Types Small Molecule, Live Attenuated Vaccine, DNA Vaccine, Recombinant Vector Vaccine, Synthetic Peptide, mRNA Vaccine, Subunit Vaccine, Monoclonal Antibody, and Vaccine
Major companies Rational Vaccines Inc, AiCuris Anti-infective Cures AG, NanoViricides Inc, Shulov Innovative Science Ltd, Abivax SA, AlphaVax Inc, Anteris Technologies Ltd, Astellas Pharma Inc, Auritec Pharmaceuticals Inc, Auro Vaccines LLC, and Biomere LLC

Key Targets in the Genital Herpes Pipeline Drugs Market

The key targets in the Genital Herpes pipeline drugs market are DNA, DNA Helicase, DNA Primase, Envelope Glycoprotein D, Lipopolysaccharide, and Matrix Metalloproteinase 9.

Genital Herpes Drugs Market, by Targets, 2021 (%)

Genital Herpes Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Genital Herpes Pipeline Drugs Market

The key mechanisms of action in the Genital Herpes Pipeline drugs market are DNA Helicase Inhibitor, DNA Primase Inhibitor, DNA Synthesis Inhibitor, Lipopolysaccharide Inhibitor, and Matrix Metalloproteinase 9 Inhibitor.

Genital Herpes Pipeline Drugs Market, by MoA, 2021 (%)

Genital Herpes Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Genital Herpes Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Genital Herpes Pipeline drugs market are Topical, Oral, Intramuscular, Vaginal, Nasal, Intradermal, Ophthalmic, and Subcutaneous.

Genital Herpes Pipeline Drugs Market Analysis, by RoA, 2021 (%)

Genital Herpes Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Genital Herpes Pipeline Drugs Market

The key molecule types in the Genital Herpes Pipeline drugs market are Small Molecule, Live Attenuated Vaccine, DNA Vaccine, Recombinant Vector Vaccine, Synthetic Peptide, mRNA Vaccine, Subunit Vaccine, Monoclonal Antibody, and Vaccine.

Genital Herpes Pipeline Drugs Market, by Molecule Type, 2021 (%)

Genital Herpes Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Genital Herpes Pipeline Drugs Market

The major companies in the Genital Herpes Pipeline drugs market are Rational Vaccines Inc, AiCuris Anti-infective Cures AG, NanoViricides Inc, Shulov Innovative Science Ltd, Abivax SA, AlphaVax Inc, Anteris Technologies Ltd, Astellas Pharma Inc, Auritec Pharmaceuticals Inc, Auro Vaccines LLC, and Biomere LLC among others.

Rational Vaccines Inc: Abivax SA (Abivax) operates as a biotechnology company. It develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce functional cure in HIV-patients and inflammatory bowel diseases caused by a dysregulated immune response to host intestinal microflora.

Genital Herpes Pipeline Drugs Market, by Major Companies, 2021 (%)

Genital Herpes Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes
  • The pipeline guide reviews pipeline therapeutics for Genital Herpes by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Genital Herpes therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Genital Herpes therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Genital Herpes

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Genital Herpes
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Genital Herpes Pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Abivax SA
AiCuris Anti-infective Cures AG
AlphaVax Inc
Anteris Technologies Ltd
Astellas Pharma Inc
Auritec Pharmaceuticals Inc
Auro Vaccines LLC
Biomere LLC
BioNTech SE
BlueWillow Biologics Inc
Brandenburg Antiinfektiva GmbH
GlaxoSmithKline Plc
iosBio Pharma Ltd
NanoViricides Inc
Nykode Therapeutics AS
Rational Vaccines Inc
Sanofi
Shulov Innovative Science Ltd
SL VaxiGen Inc
Starpharma Holdings Ltd
United BioPharma Inc
Vaxart Inc
Vir Biotechnology Inc
Vironova Medical AB
Wuhan Binhui Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Genital Herpes – Overview

Genital Herpes – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Genital Herpes – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Genital Herpes – Companies Involved in Therapeutics Development

Genital Herpes – Drug Profiles

Genital Herpes – Dormant Projects

Genital Herpes – Discontinued Products

Genital Herpes – Product Development Milestones

Featured News & Press Releases

Oct 18, 2021: United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University partner on world’s first long-acting Herpes Treatment UB-621

Jul 22, 2021: Rational Vaccines receives UK MHRA Innovation Passport for RVx201 for the treatment of genital herpes resulting from herpes simplex type 2 (HSV-2) virus

Nov 10, 2020: United BioPharma received IND approval from China NMPA for UB-621 Phase 2 trial in patients with Recurrent Genital Herpes

Sep 20, 2019: New Penn-Developed Vaccine Prevents Herpes in Mice, Guinea Pigs

Jun 10, 2019: United BioPharma receives US FDA approval for UB-621 Phase 2 trial in recurrent Genital Herpes Patients

Dec 06, 2017: Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates

May 04, 2017: Admedus Releases Results of HSV-2 Phase IIa Study

Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine

Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data

Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging

Feb 03, 2016: Model helps decide drug dose for clinical testing

Nov 15, 2015: IND submission of a phase I clinical trial for UB-621, an Anti-HSV-gD antibody, was approved by Taiwan Food and Drug Administration (TFDA)

Sep 22, 2015: NanoBio’s Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine

Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Genital Herpes, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Genital Herpes – Pipeline by Abivax SA, 2022

Genital Herpes – Pipeline by AiCuris Anti-infective Cures AG, 2022

Genital Herpes – Pipeline by AlphaVax Inc, 2022

Genital Herpes – Pipeline by Anteris Technologies Ltd, 2022

Genital Herpes – Pipeline by Astellas Pharma Inc, 2022

Genital Herpes – Pipeline by Auritec Pharmaceuticals Inc, 2022

Genital Herpes – Pipeline by Auro Vaccines LLC, 2022

Genital Herpes – Pipeline by Biomere LLC, 2022

Genital Herpes – Pipeline by BioNTech SE, 2022

Genital Herpes – Pipeline by BlueWillow Biologics Inc, 2022

Genital Herpes – Pipeline by Brandenburg Antiinfektiva GmbH, 2022

Genital Herpes – Pipeline by GlaxoSmithKline Plc, 2022

Genital Herpes – Pipeline by iosBio Pharma Ltd, 2022

Genital Herpes – Pipeline by NanoViricides Inc, 2022

Genital Herpes – Pipeline by Nykode Therapeutics AS, 2022

Genital Herpes – Pipeline by Rational Vaccines Inc, 2022

Genital Herpes – Pipeline by Sanofi, 2022

Genital Herpes – Pipeline by Shulov Innovative Science Ltd, 2022

Genital Herpes – Pipeline by SL VaxiGen Inc, 2022

Genital Herpes – Pipeline by Starpharma Holdings Ltd, 2022

Genital Herpes – Pipeline by United BioPharma Inc, 2022

Genital Herpes – Pipeline by Vaxart Inc, 2022

Genital Herpes – Pipeline by Vir Biotechnology Inc, 2022

Genital Herpes – Pipeline by Vironova Medical AB, 2022

Genital Herpes – Pipeline by Wuhan Binhui Biotechnology Co Ltd, 2022

Genital Herpes – Dormant Projects, 2022

Genital Herpes – Dormant Projects, 2022 (Contd..1)

Genital Herpes – Dormant Projects, 2022 (Contd..2)

Genital Herpes – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Genital Herpes, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.